Cargando…
Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria
The consequences of the SARS-CoV-2 pandemic have exceeded any forecast made. Today we know that the level of severity of the infection in its initial stages will correspond to the evolution and the presence of sequelae in the future. There are no specific treatments that have shown sufficient eviden...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316068/ https://www.ncbi.nlm.nih.gov/pubmed/34454827 http://dx.doi.org/10.1016/j.semerg.2021.06.009 |
_version_ | 1783729808935485440 |
---|---|
author | García-Matarín, L. Velilla-Zancada, S. Trillo-Calvo, E. Molina-Escribano, F. Serrano-Cumplido, A. |
author_facet | García-Matarín, L. Velilla-Zancada, S. Trillo-Calvo, E. Molina-Escribano, F. Serrano-Cumplido, A. |
author_sort | García-Matarín, L. |
collection | PubMed |
description | The consequences of the SARS-CoV-2 pandemic have exceeded any forecast made. Today we know that the level of severity of the infection in its initial stages will correspond to the evolution and the presence of sequelae in the future. There are no specific treatments that have shown sufficient evidence to allow their recommendation, especially in the mild-moderate stages of the disease. The anti-Covid vaccination is showing clear benefits, both in the prevention of the disease and in its evolution, with the consequent improvement in the numbers of those affected by the pandemic. The use of different drugs used in other indications has been proposed as possible beneficial treatments for COVID-19 that, if used, will be prescribed individually taking into account the characteristics and situation of the patient, the evolutionary phase of the disease as well as well as the limitations of the lack of evidence in its administration. |
format | Online Article Text |
id | pubmed-8316068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83160682021-07-28 Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria García-Matarín, L. Velilla-Zancada, S. Trillo-Calvo, E. Molina-Escribano, F. Serrano-Cumplido, A. Semergen Revisión The consequences of the SARS-CoV-2 pandemic have exceeded any forecast made. Today we know that the level of severity of the infection in its initial stages will correspond to the evolution and the presence of sequelae in the future. There are no specific treatments that have shown sufficient evidence to allow their recommendation, especially in the mild-moderate stages of the disease. The anti-Covid vaccination is showing clear benefits, both in the prevention of the disease and in its evolution, with the consequent improvement in the numbers of those affected by the pandemic. The use of different drugs used in other indications has been proposed as possible beneficial treatments for COVID-19 that, if used, will be prescribed individually taking into account the characteristics and situation of the patient, the evolutionary phase of the disease as well as well as the limitations of the lack of evidence in its administration. Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. 2022-03 2021-07-28 /pmc/articles/PMC8316068/ /pubmed/34454827 http://dx.doi.org/10.1016/j.semerg.2021.06.009 Text en © 2021 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Revisión García-Matarín, L. Velilla-Zancada, S. Trillo-Calvo, E. Molina-Escribano, F. Serrano-Cumplido, A. Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria |
title | Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria |
title_full | Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria |
title_fullStr | Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria |
title_full_unstemmed | Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria |
title_short | Fármacos potencialmente útiles en el tratamiento de la COVID-19 en Atención Primaria |
title_sort | fármacos potencialmente útiles en el tratamiento de la covid-19 en atención primaria |
topic | Revisión |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316068/ https://www.ncbi.nlm.nih.gov/pubmed/34454827 http://dx.doi.org/10.1016/j.semerg.2021.06.009 |
work_keys_str_mv | AT garciamatarinl farmacospotencialmenteutileseneltratamientodelacovid19enatencionprimaria AT velillazancadas farmacospotencialmenteutileseneltratamientodelacovid19enatencionprimaria AT trillocalvoe farmacospotencialmenteutileseneltratamientodelacovid19enatencionprimaria AT molinaescribanof farmacospotencialmenteutileseneltratamientodelacovid19enatencionprimaria AT serranocumplidoa farmacospotencialmenteutileseneltratamientodelacovid19enatencionprimaria |